Efficacy & Safety of Ixekizumab ± Methotrexate in PsA (52-Week SPIRIT-H2H)

Amber Hudgins, PharmD, CPP, discusses the efficacy and safety of ixekizumab in biologic-naive patients with psoriatic arthritis, comparing it to adalimumab with and without methotrexate. She dives into the results of the SPIRIT-H2H study, highlighting key findings on joint and skin improvements at 52 weeks. Amber explains how ixekizumab delivers consistent efficacy regardless of methotrexate use, offering valuable insights for evidence-based treatment decisions in PsA management